Based on the results of the NORPACT-1 trial presented at ASCO 2023, would you offer upfront surgery or neoadjuvant chemotherapy to early stage pancreatic ductal adenocarcinoma?

Do the results of the NORPACT-1 trial change your practice in resectable PDAC?

• Upfront surgery (did not change practice)
• Neoadjuvant FFX (did not change practice)
• Upfront surgery (changed practice)
• Other